<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Emery-Dreifuss muscular dystrophy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Emery-Dreifuss muscular dystrophy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Emery-Dreifuss muscular dystrophy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Basil T Darras, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marc C Patterson, MD, FRACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 23, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The muscular dystrophies are an inherited group of progressive myopathic disorders resulting from defects in a number of genes required for normal muscle function. Some of the genes responsible for these conditions have been identified. Muscle weakness is the primary symptom.
        </p>
        <p>
         Clinical aspects of Emery-Dreifuss muscular dystrophy (EDMD), also known as humeroperoneal muscular dystrophy, are discussed here. Other muscular dystrophies are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/6149.html" rel="external">
          "Duchenne and Becker muscular dystrophy: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5147.html" rel="external">
          "Myotonic dystrophy: Etiology, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/87096.html" rel="external">
          "Facioscapulohumeral muscular dystrophy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6190.html" rel="external">
          "Limb-girdle muscular dystrophy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6180.html" rel="external">
          "Oculopharyngeal, distal, and congenital muscular dystrophies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H354612653">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         EDMD is an uncommon if not rare disorder, although its overall incidence and prevalence are not known [
         <a href="#rid1">
          1
         </a>
         ]. In a meta-analysis, the pooled prevalence of EDMD in all age groups was 0.39 per 100,000 [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          GENETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         EDMD is a genetically heterogenous disorder with X-linked recessive, autosomal dominant, and autosomal recessive forms [
         <a href="#rid3">
          3
         </a>
         ]. Several forms are considered nuclear envelopathies because they are associated with mutations in genes encoding nuclear membrane proteins, including the
         <em>
          EMD
         </em>
         gene that encodes for emerin, the
         <em>
          LMNA
         </em>
         gene that encodes for lamin A and lamin C, and the
         <em>
          SYNE1
         </em>
         and
         <em>
          SYNE2
         </em>
         genes that encode for nesprin 1 and nesprin 2, respectively [
         <a href="#rid4">
          4
         </a>
         ]. The most common type is autosomal dominant EDMD caused by a heterozygous
         <em>
          LMNA
         </em>
         mutation, followed by X-linked EDMD caused by
         <em>
          EMD
         </em>
         or
         <em>
          FHL1
         </em>
         mutations [
         <a href="#rid1">
          1
         </a>
         ]. There are only a few reports of autosomal recessive EDMD. In a high proportion of EDMD cases, the genetic defect remains unknown [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          X-linked forms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The X-linked forms of the disorder are EDMD1 and EDMD6:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <em>
          EMD
         </em>
         gene on Xq28 (EDMD1) encodes emerin, a protein that is localized to the nuclear envelope [
         <a href="#rid6">
          6-9
         </a>
         ]. Most mutations are null mutations resulting in complete loss of emerin expression in muscle. Missense mutations are associated with decreased or even normal amounts of emerin and result in a milder phenotype.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <em>
          FHL1
         </em>
         gene on Xq26.3 (EDMD6) encodes the four-and-a-half LIM domains protein 1 and is associated with an X-linked EDMD phenotype with hypertrophic cardiomyopathy [
         <a href="#rid10">
          10,11
         </a>
         ]. Mutations in the
         <em>
          FHL1
         </em>
         gene result in delayed myotube formation [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The nomenclature and classification of
         <em>
          FHL1
         </em>
         -linked myopathies/muscular dystrophies is still evolving. In addition to EDMD6,
         <em>
          FHL1
         </em>
         mutations have also been identified in patients with X-linked myopathy with postural muscle atrophy, X-linked dominant scapuloperoneal myopathy, X-linked reducing body myopathy with early childhood onset, and myofibrillar myopathy [
         <a href="#rid12">
          12,13
         </a>
         ]. Common features of
         <em>
          FHL1
         </em>
         disorders include joint contractures, spinal rigidity, and cardiac involvement. Reducing body aggregates in muscle biopsies are a characteristic feature of reducing body myopathy and scapuloperoneal myopathy. In contrast, muscle biopsies of patients with EDMD6 do not show reducing bodies, but the expression of FHL1A protein is moderately to severely decreased [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Autosomal dominant and recessive forms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both an autosomal dominant (EDMD2) and a rare autosomal recessive (EDMD3) form are linked to mutations of the
         <em>
          LMNA
         </em>
         gene on chromosome 1q21.2 that encodes for lamin A and lamin C, two A-type lamins found in the nuclear envelope [
         <a href="#rid14">
          14-16
         </a>
         ].
        </p>
        <p>
         Other EDMD-like phenotypes with autosomal dominant inheritance are linked to mutations of
         <em>
          SYNE1
         </em>
         (EDMD4) and
         <em>
          SYNE2
         </em>
         (EDMD5), both of which encode for nuclear envelope proteins [
         <a href="#rid3">
          3,17
         </a>
         ]. However, the number of reported cases is small and thus the muscle phenotype remains to be defined.
        </p>
        <p>
         Mutations in the
         <em>
          TMEM43
         </em>
         gene, which encodes another nuclear envelope protein called LUMA, are also associated with an autosomal dominant EDMD-like phenotype (EDMD7) [
         <a href="#rid18">
          18
         </a>
         ]. Such mutations were found in 2 of 41 patients with EDMD-related myopathy. As with
         <em>
          SYNE1
         </em>
         and
         <em>
          SYNE2
         </em>
         , additional data are needed to further delineate the phenotype of
         <em>
          TMEM43
         </em>
         -related myopathy [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Laminopathies
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to EDMD2 and EDMD3, a number of other laminopathies (ie, disorders caused by
         <em>
          LMNA
         </em>
         gene mutations) have been identified [
         <a href="#rid20">
          20
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Limb-girdle muscular dystrophy with atrioventricular conduction defects (LGMD1B) (see
         <a class="medical medical_review" href="/z/d/html/6190.html" rel="external">
          "Limb-girdle muscular dystrophy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autosomal dominant dilated cardiomyopathy with conduction defects (CMD1A or DCM-CD) [
         <a href="#rid21">
          21,22
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autosomal dominant dilated cardiomyopathy with apical left ventricular aneurysm [
         <a href="#rid23">
          23
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autosomal dominant quadriceps myopathy with dilated cardiomyopathy and associated conduction defects [
         <a href="#rid24">
          24
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A relatively severe form of congenital muscular dystrophy classified as
         <em>
          LMNA
         </em>
         -related congenital muscular dystrophy [
         <a href="#rid25">
          25-27
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Charcot-Marie-Tooth type 2B1 [
         <a href="#rid28">
          28
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Familial partial lipodystrophy type 2 (see
         <a class="medical medical_review" href="/z/d/html/1788.html" rel="external">
          "Lipodystrophic syndromes", section on 'FPLD type 2'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mandibuloacral dysplasia (see
         <a class="medical medical_review" href="/z/d/html/1788.html" rel="external">
          "Lipodystrophic syndromes", section on 'Mandibuloacral dysplasia'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hutchinson-Gilford progeria syndrome [
         <a href="#rid29">
          29
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dilated cardiomyopathy and hypergonadotropic hypogonadism (atypical Werner syndrome) [
         <a href="#rid30">
          30
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Restrictive dermopathy (also known as tight skin contracture syndrome), a lethal neonatal laminopathy [
         <a href="#rid31">
          31
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Several reports have found patients harboring mutations in both EMD and
         <em>
          LMNA
         </em>
         genes [
         <a href="#rid32">
          32,33
         </a>
         ]. The clinical presentations included severe EDMD, a combination of Charcot-Marie-Tooth type 2 and EDMD, and isolated cardiomyopathy.
        </p>
        <p>
         Mutations in both emerin and desmin genes were found in a patient with cardioskeletal myopathy [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H967340517">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major features of EDMD are early contractures, slowly progressive humeroperoneal muscle weakness/wasting, and cardiac disease with conduction defects, arrhythmias, and cardiomyopathy [
         <a href="#rid3">
          3,5,34
         </a>
         ]. The different forms of EDMD have generally similar symptoms, which usually begin in the first or second decade of life. However, the disease exhibits significant inter- and intra-familial variability with regard to age at onset, severity, and progression of the major manifestations [
         <a href="#rid35">
          35
         </a>
         ]. Cases of adult onset with slow progression have been observed.
        </p>
        <p class="headingAnchor" id="H967340544">
         <span class="h2">
          Symptoms and signs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contractures at the elbows are noted early and are commonly the first manifestations of EDMD. Contractures of the posterior aspect of the neck, the entire spine, and the Achilles tendons also occur. Achilles tendon contractures are frequently associated with toe walking. Severe spine and leg contractures eventually may lead to loss of ambulation.
        </p>
        <p>
         Muscle weakness and wasting has a humeroperoneal distribution; it typically begins in the arms, involving both the biceps and triceps, with relative preservation of the deltoid muscles. Subsequently, distal leg weakness with atrophy of the peroneal muscles is noted. In some cases, mild facial weakness may also be observed. The myopathy tends to be slowly progressive during the first three decades of life, but more rapid thereafter.
        </p>
        <p>
         A dilated cardiomyopathy is seen in most patients with EDMD. It is typically associated with atrioventricular conduction abnormalities such as first-degree atrioventricular block, but also with sinus bradycardia or supraventricular tachycardia, which may be early signs of cardiac involvement [
         <a href="#rid36">
          36
         </a>
         ]. Other findings include atrial paralysis, atrial fibrillation, and atrial flutter; these are most common in EDMD1. Symptoms of hypoperfusion (syncope or near syncope) often result from infranodal or atrioventricular conduction block with the development of slow junctional rhythms, requiring pacemaker insertion [
         <a href="#rid37">
          37-39
         </a>
         ]. The onset of cardiac abnormalities is usually in the third decade of life but earlier onset has been observed [
         <a href="#rid22">
          22
         </a>
         ]. Sudden death may develop in patients not previously diagnosed because they have little or no skeletal myopathy [
         <a href="#rid39">
          39
         </a>
         ]. There is no correlation between the degree of neuromuscular involvement and the severity of cardiac abnormalities [
         <a href="#rid40">
          40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4943.html" rel="external">
          "Definition and classification of the cardiomyopathies"
         </a>
         .)
        </p>
        <p>
         EDMD6 is associated with hypertrophic cardiomyopathy [
         <a href="#rid10">
          10,11
         </a>
         ]. (See
         <a class="local">
          'X-linked forms'
         </a>
         above.)
        </p>
        <p>
         Arrhythmogenic dilated cardiomyopathy, cardiac failure, and ventricular tachyarrhythmias are more common and more severe in autosomal dominant EDMD2 (due to
         <em>
          LMNA
         </em>
         mutations) [
         <a href="#rid41">
          41,42
         </a>
         ] but also occur in X-linked EDMD1 (caused by
         <em>
          EMD
         </em>
         mutations) [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">
          "Determining the etiology and severity of heart failure or cardiomyopathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4943.html" rel="external">
          "Definition and classification of the cardiomyopathies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H967340762">
         <span class="h2">
          Laboratory studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         EDMD is associated with abnormalities in serum creatine kinase (CK), electrocardiography (ECG), electromyography (EMG), muscle imaging, and muscle biopsy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A modest elevation of serum CK concentration, rarely higher than a few hundred units/L, is typical. Increases up to 20 times the upper limit of normal sometimes occur, but may be seen more often in the early stages of the disease. CK levels are not useful in the identification of carriers because, even in obligate carriers, they tend to be normal [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The ECG may show varying degrees of atrioventricular block, small T waves, and atrial arrhythmias.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The EMG usually displays myopathic features and may also reveal evidence of denervation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The muscle biopsy typically shows mild myopathic changes characterized by internal nuclei, variation in fiber size, focal connective tissue proliferation, and occasional necrotic fibers. Inflammatory changes have been noted in the muscle biopsies of some children (≤2 years of age) with infantile LMNA myopathy [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Muscle immunohistochemistry will reveal absence of nuclear staining for emerin in approximately 95 percent of patients with X-linked EDMD [
         <a href="#rid45">
          45
         </a>
         ]. No
         <em>
          EMD
         </em>
         gene mutations have been detected in patients who were emerin-positive, which underscores the diagnostic value of muscle immunohistochemistry [
         <a href="#rid42">
          42
         </a>
         ]. Emerin can also be detected by immunofluorescence and/or western blot testing in muscle and other tissues including skin, exfoliative buccal cells, lymphocytes, and lymphoblastoid cell lines [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with EDMD, leg muscle imaging reveals more severe changes in posterior calf muscles with selective involvement of the soleus in EDMD1 and of the medial gastrocnemius muscle in EDMD2; the magnetic resonance imaging (MRI) abnormalities are mild or moderate in other leg muscles [
         <a href="#rid48">
          48
         </a>
         ]. The pattern is similar in asymptomatic carriers and in patients with various phenotypes caused by
         <em>
          LMNA
         </em>
         gene mutations [
         <a href="#rid49">
          49
         </a>
         ]. The rectus femoris muscle is spared [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          EVALUATION AND DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H4179054826">
         <span class="h2">
          Establishing the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical diagnosis of EDMD can be made for patients with the cardinal features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early contractures of elbow flexors, ankle plantar flexors, and spine
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Childhood onset of humeroperoneal weakness and wasting
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac disease with conduction defects, arrhythmias, and cardiomyopathy, which may present later in life
        </p>
        <p>
        </p>
        <p>
         The diagnosis of EDMD is established in a patient with a compatible clinical phenotype by genetic testing that identifies a hemizygous pathogenic variant in
         <em>
          EMD
         </em>
         or
         <em>
          FHL1
         </em>
         , a heterozygous pathogenic variant in
         <em>
          LMNA
         </em>
         , or rarely biallelic pathogenic variants in
         <em>
          LMNA
         </em>
         [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Genetic testing should be ordered as the first diagnostic study in patients with a phenotype suggestive of EDMD (
         <a class="graphic graphic_algorithm graphicRef100447" href="/z/d/graphic/100447.html" rel="external">
          algorithm 1
         </a>
         ); muscle biopsy is an invasive and less informative procedure [
         <a href="#rid40">
          40
         </a>
         ]. Electromyography and muscle biopsy may be useful in atypical cases, such as patients without a classic phenotype or those lacking a family history.
        </p>
        <p class="headingAnchor" id="H3717987732">
         <span class="h2">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approaches to genetic testing differ according to phenotype and mode of inheritance.
        </p>
        <p class="headingAnchor" id="H3704264275">
         <span class="h3">
          EDMD phenotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with a phenotype suggestive of EDMD, single gene testing or multigene panel testing is used to establish the genetic diagnosis [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Single gene testing
         </strong>
         – Single gene testing is appropriate for the following situations:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          In a male with a family history suggesting X-linked inheritance or those with no or unknown family history
         </strong>
         , testing for
         <em>
          EMD
         </em>
         pathogenic variants should be performed first, followed by genetic testing for the
         <em>
          FHL1
         </em>
         gene if no
         <em>
          EMD
         </em>
         mutation is found. The proportion of cases with an EDMD phenotype and an X-linked inheritance pattern attributed to
         <em>
          EMD
         </em>
         gene mutations is approximately 60 percent, whereas the proportion attributed to
         <em>
          FHL1
         </em>
         mutations is approximately 10 percent [
         <a href="#rid10">
          10,19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          In cases with a family history suggesting autosomal dominant or recessive inheritance
         </strong>
         ,
         <em>
          LMNA
         </em>
         -related disease is most likely. In patients with autosomal dominant EDMD, gene sequence analysis or mutation scanning will detect
         <em>
          LMNA
         </em>
         sequence variants in about 45 percent of patients [
         <a href="#rid19">
          19
         </a>
         ]. For those without
         <em>
          LMNA
         </em>
         mutations, testing can proceed to evaluate for autosomal dominant pathogenic variants in
         <em>
          SYNE1
         </em>
         ,
         <em>
          SYNE2
         </em>
         , and
         <em>
          TMEM43
         </em>
         genes (
         <a class="graphic graphic_algorithm graphicRef100447" href="/z/d/graphic/100447.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          In cases without a clear inheritance pattern
         </strong>
         ,
         <em>
          LMNA
         </em>
         -related disease is most likely, followed by
         <em>
          EMD-
         </em>
         and then
         <em>
          FHL1
         </em>
         -related disease [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          In a female who represents a single occurrence in a family
         </strong>
         , the
         <em>
          LMNA
         </em>
         gene should be screened first as
         <em>
          LMNA
         </em>
         -related disease is more likely than an X-linked EDMD [
         <a href="#rid19">
          19,40
         </a>
         ]. Carrier females only rarely manifest symptoms of X-linked EDMD. (See
         <a class="local">
          'Autosomal dominant and recessive forms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multigene panel testing
         </strong>
         – A multigene panel is an alternative to single gene testing for all patients suspected of EDMD based upon phenotype. The panel should include
         <em>
          EMD
         </em>
         ,
         <em>
          FHL1
         </em>
         ,
         <em>
          LMNA
         </em>
         ,
         <em>
          SYNE1
         </em>
         ,
         <em>
          SYNE2
         </em>
         , and
         <em>
          TMEM43
         </em>
         , as well as other genes of interest (see
         <a class="local">
          'Differential diagnosis'
         </a>
         below) [
         <a href="#rid19">
          19
         </a>
         ]. This approach is considered most likely to disclose the pathogenic variant causing the condition in a cost-effective manner [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Gene panels are widely available, but the clinician has to make sure that deletion/duplication analysis is included in the testing as well.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1929001453">
         <span class="h3">
          Atypical phenotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         In atypical cases where the clinical diagnosis of EDMD or other specific myopathies is not evident, the best approach is comprehensive genomic testing using next generation sequencing techniques (which does not require the clinician to determine which candidate genes are likely involved). Exome sequencing is most commonly used; genomic sequencing is an alternative.
        </p>
        <p>
         Exome microarray to detect single-exon deletions or duplications may be ordered (where available) if exome sequencing is not diagnostic. However, the incidence of deletions/duplications in the three main EDMD genes (
         <em>
          EMD
         </em>
         ,
         <em>
          FHL1
         </em>
         ,
         <em>
          LMNA
         </em>
         ) is very low.
        </p>
        <p>
         In very atypical cases, some clinicians obtain a muscle biopsy and/or electromyography before proceeding with genetic testing. However, this is not the most cost-effective approach, given that the exome sequencing is now significantly less expensive than when it was first available.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other than the different inherited muscular dystrophies and myopathies, the differential diagnosis of EDMD includes the rigid spine syndrome (RSS). This disorder is usually associated with limited flexion of the spine, a relatively mild and slowly progressive myopathy, and elbow and ankle contractures [
         <a href="#rid50">
          50
         </a>
         ]. Some patients with RSS develop cor pulmonale with right heart involvement due to restrictive chest wall movement and respiratory muscle weakness [
         <a href="#rid51">
          51
         </a>
         ]. Early and severe scoliosis in the first decade is in favor of RSS. Severe respiratory involvement is usually present in RSS but is unusual in EDMD [
         <a href="#rid40">
          40
         </a>
         ]. Mutations in the selenoprotein N1 gene (
         <em>
          SEPN1
         </em>
         ) have been identified in a subset of patients with RSS (RSMD1). (See
         <a class="medical medical_review" href="/z/d/html/6150.html" rel="external">
          "Congenital myopathies", section on 'Multiminicore disease'
         </a>
         .)
        </p>
        <p>
         An Emery-Dreifuss-like phenotype with limb-girdle weakness and early onset of joint contractures, but without cardiomyopathy, is caused by mutations of the
         <em>
          TTN
         </em>
         gene [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no disease modifying therapy for EDMD. Management is mainly supportive [
         <a href="#rid5">
          5
         </a>
         ]. Cardiomyopathy and conduction system defects are major problems, as discussed in the following section. (See
         <a class="local">
          'Cardiac issues'
         </a>
         below.)
        </p>
        <p>
         Physical therapy should focus on stretching exercises to prevent the early development of contractures [
         <a href="#rid19">
          19
         </a>
         ]. Other interventions include orthopedic procedures to release contractures, spinal fusion for severe scoliosis, walking aids (eg, canes walkers, orthoses, wheelchairs) to facilitate mobility, and, rarely, respiratory aids in the late stages of the disease.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Cardiac issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         The principal concern in the patient with EDMD is death resulting from cardiac involvement. The cardiac status of the patient should therefore be investigated, even in asymptomatic patients, with a referral for cardiology assessment at the time of diagnosis [
         <a href="#rid53">
          53
         </a>
         ]. Patients with autosomal dominant EDMD and X-linked recessive forms of EDMD should have annual follow-up with electrocardiography (ECG), echocardiography, and ambulatory ECG; patients with autosomal recessive EDMD should have annual ECG and ambulatory ECG. (See
         <a class="local">
          'Prognosis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">
          "Determining the etiology and severity of heart failure or cardiomyopathy"
         </a>
         .)
        </p>
        <p>
         Cardiac intervention is required to treat arrhythmias, heart failure, and conduction defects [
         <a href="#rid19">
          19
         </a>
         ]. Placement of a cardiac pacemaker alone is insufficient to prevent sudden cardiac death [
         <a href="#rid54">
          54
         </a>
         ]. An implantable cardioverter defibrillator can be lifesaving in patients with evidence of atrioventricular block [
         <a href="#rid55">
          55
         </a>
         ]. Therefore, patients with EDMD and cardiac involvement require primary placement of combined pacemaker with an implantable cardiac defibrillator [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/941.html" rel="external">
          "Permanent cardiac pacing: Overview of devices and indications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/921.html" rel="external">
          "Implantable cardioverter-defibrillators: Overview of indications, components, and functions"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">
          "Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4950.html" rel="external">
          "Hypertrophic cardiomyopathy: Management of patients without outflow tract obstruction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/119625.html" rel="external">
          "Hypertrophic cardiomyopathy: Management of ventricular arrhythmias and sudden cardiac death risk"
         </a>
         .)
        </p>
        <p>
         Cardiac transplantation may be an option in selected patients with EDMD [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3528.html" rel="external">
          "Heart transplantation in adults: Indications and contraindications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Potential problems related to anesthesia should be anticipated for patients with EDMD undergoing surgery, which may be required to manage orthopedic complications of the disease [
         <a href="#rid19">
          19,57
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac pacing (temporary or permanent) should be available perioperatively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anesthetic agents with myocardial depressant activity should be avoided in patients with significant cardiomyopathy. (See
         <a class="medical medical_review" href="/z/d/html/105407.html" rel="external">
          "Perioperative management of heart failure in patients undergoing noncardiac surgery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91654.html" rel="external">
          "Intraoperative management for noncardiac surgery in patients with heart failure"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neck flexion may be markedly reduced, causing difficulty with endotracheal intubation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flexion contractures of the cervical and lumbar paravertebral muscles may interfere with spinal and epidural anesthesia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          Succinylcholine
         </a>
         is contraindicated because patients with degenerative or dystrophic neuromuscular disease are at increased risk for the development of severe hyperkalemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rhabdomyolysis, hyperkalemia, or other catabolic reactions in muscle have not been described in EDMD. However, episodes that mimic malignant hyperthermia have been reported in other muscular dystrophies and neuromuscular disorders, with clinical manifestations that include rhabdomyolysis, hyperkalemia, and sudden cardiac arrest [
         <a href="#rid58">
          58-60
         </a>
         ]. Thus, we recommend avoidance of potential triggering agents such as depolarizing muscle relaxants (eg,
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         ) and volatile anesthetic drugs (eg, halothane,
         <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">
          isoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="8891" href="/z/d/drug information/8891.html" rel="external">
          desflurane
         </a>
         , and
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/403.html" rel="external">
          "Susceptibility to malignant hyperthermia: Evaluation and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H692740689">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most cases of EDMD, muscle weakness and atrophy are slowly progressive during the first three decades of life but advance more rapidly thereafter [
         <a href="#rid35">
          35
         </a>
         ]. Most patients remain ambulatory for many years and seldom if ever develop profound motor or respiratory dysfunction [
         <a href="#rid1">
          1
         </a>
         ]. Loss of ambulation is seen more often with autosomal dominant EDMD and is unusual in X-linked EDMD [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Patients with EDMD are at risk of death from advanced atrioventricular block and from progressive heart failure. The onset of cardiac abnormalities usually occurs in the third decade in EDMD. Earlier onset of severe involvement is rare [
         <a href="#rid61">
          61-63
         </a>
         ], but may occur; there is a least one reported case of serious ventricular arrhythmia in a young patient with EDMD1 [
         <a href="#rid36">
          36
         </a>
         ]. Cardiac involvement is more aggressive in EDMD2 [
         <a href="#rid64">
          64
         </a>
         ]; ventricular arrhythmias occur earlier and lead to dilated cardiomyopathy [
         <a href="#rid22">
          22,41
         </a>
         ]. Sudden death can occur, more frequently in EDMD2, but also in EDMD1. There is no correlation between the severity of the neuromuscular involvement and the degree of cardiac abnormality [
         <a href="#rid61">
          61,65,66
         </a>
         ]. (See
         <a class="local">
          'Cardiac issues'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2069223505">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/121073.html" rel="external">
          "Society guideline links: Muscular dystrophy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15489.html" rel="external">
          "Patient education: Muscular dystrophy (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/725.html" rel="external">
          "Patient education: Overview of muscular dystrophies (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Emery-Dreifuss muscular dystrophy (EDMD) is a genetically heterogenous disorder. The most common type is autosomal dominant EDMD caused by a heterozygous
         <em>
          LMNA
         </em>
         mutation, followed by X-linked EDMD caused by
         <em>
          EMD
         </em>
         or
         <em>
          FHL1
         </em>
         mutations. (See
         <a class="local">
          'Genetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The onset of symptoms from EDMD usually occurs in the first or second decade of life. The cardinal features are early contractures, childhood onset of slowly progressive humeroperoneal muscle weakness/wasting, and cardiac disease with conduction defects, arrhythmias, and cardiomyopathy. (See
         <a class="local">
          'Symptoms and signs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laboratory findings in EDMD include elevation of serum creatine kinase (typically modest but sometimes severe), electrocardiography abnormalities (eg, atrioventricular block, small T waves, atrial arrhythmias), and myopathic features on electromyography (EMG) and muscle biopsy. (See
         <a class="local">
          'Laboratory studies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In cases with typical clinical features of EDMD and a supportive family history, single gene testing may confirm the diagnosis (
         <a class="graphic graphic_algorithm graphicRef100447" href="/z/d/graphic/100447.html" rel="external">
          algorithm 1
         </a>
         ). In cases with early contractures that otherwise lack typical features of EDMD, the presence of myopathic changes on EMG and muscle biopsy is supportive of EDMD. However, multigene panel testing may be more cost-effective and specific for EDMD. (See
         <a class="local">
          'Evaluation and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is no disease modifying therapy for EDMD. Management is supportive. Cardiac interventions may be required to treat arrhythmias, heart failure, and conduction defects. (See
         <a class="local">
          'Management'
         </a>
         above and
         <a class="local">
          'Cardiac issues'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Potential problems related to anesthesia should be anticipated for patients with EDMD undergoing surgery. (See
         <a class="local">
          'Anesthesia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most patients with EDMD remain ambulatory for many years and seldom if ever develop profound motor or respiratory dysfunction. However, loss of ambulation can occur and is seen more often with autosomal dominant EDMD than with X-linked EDMD. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bonne G, Quijano-Roy S. Emery-Dreifuss muscular dystrophy, laminopathies, and other nuclear envelopathies. Handb Clin Neurol 2013; 113:1367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mah JK, Korngut L, Fiest KM, et al. A Systematic Review and Meta-analysis on the Epidemiology of the Muscular Dystrophies. Can J Neurol Sci 2016; 43:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puckelwartz M, McNally EM. Emery-Dreifuss muscular dystrophy. Handb Clin Neurol 2011; 101:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worman HJ, Ostlund C, Wang Y. Diseases of the nuclear envelope. Cold Spring Harb Perspect Biol 2010; 2:a000760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heller SA, Shih R, Kalra R, Kang PB. Emery-Dreifuss muscular dystrophy. Muscle Nerve 2020; 61:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yates JR, Warner JP, Smith JA, et al. Emery-Dreifuss muscular dystrophy: linkage to markers in distal Xq28. J Med Genet 1993; 30:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bione S, Maestrini E, Rivella S, et al. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet 1994; 8:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagano A, Koga R, Ogawa M, et al. Emerin deficiency at the nuclear membrane in patients with Emery-Dreifuss muscular dystrophy. Nat Genet 1996; 12:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuchiya Y, Hase A, Ogawa M, et al. Distinct regions specify the nuclear membrane targeting of emerin, the responsible protein for Emery-Dreifuss muscular dystrophy. Eur J Biochem 1999; 259:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gueneau L, Bertrand AT, Jais JP, et al. Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2009; 85:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Windpassinger C, Schoser B, Straub V, et al. An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1. Am J Hum Genet 2008; 82:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cowling BS, Cottle DL, Wilding BR, et al. Four and a half LIM protein 1 gene mutations cause four distinct human myopathies: a comprehensive review of the clinical, histological and pathological features. Neuromuscul Disord 2011; 21:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selcen D, Bromberg MB, Chin SS, Engel AG. Reducing bodies and myofibrillar myopathy features in FHL1 muscular dystrophy. Neurology 2011; 77:1951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raffaele Di Barletta M, Ricci E, Galluzzi G, et al. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2000; 66:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonne G, Di Barletta MR, Varnous S, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999; 21:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jimenez-Escrig A, Gobernado I, Garcia-Villanueva M, Sanchez-Herranz A. Autosomal recessive Emery-Dreifuss muscular dystrophy caused by a novel mutation (R225Q) in the lamin A/C gene identified by exome sequencing. Muscle Nerve 2012; 45:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Q, Bethmann C, Worth NF, et al. Nesprin-1 and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. Hum Mol Genet 2007; 16:2816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang WC, Mitsuhashi H, Keduka E, et al. TMEM43 mutations in Emery-Dreifuss muscular dystrophy-related myopathy. Ann Neurol 2011; 69:1005.
          </a>
         </li>
         <li class="breakAll">
          Bonne G, Leturcq F, Ben Yaou R. Emery-Dreifuss muscular dystrophy. GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK1436/ (Accessed on March 23, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carboni N, Mateddu A, Marrosu G, et al. Genetic and clinical characteristics of skeletal and cardiac muscle in patients with lamin A/C gene mutations. Muscle Nerve 2013; 48:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999; 341:1715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bécane HM, Bonne G, Varnous S, et al. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing Clin Electrophysiol 2000; 23:1661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forissier JF, Bonne G, Bouchier C, et al. Apical left ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation. Eur J Heart Fail 2003; 5:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charniot JC, Pascal C, Bouchier C, et al. Functional consequences of an LMNA mutation associated with a new cardiac and non-cardiac phenotype. Hum Mutat 2003; 21:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quijano-Roy S, Mbieleu B, Bönnemann CG, et al. De novo LMNA mutations cause a new form of congenital muscular dystrophy. Ann Neurol 2008; 64:177.
          </a>
         </li>
         <li class="breakAll">
          Darras BT. Unpublished observations, 2009.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komaki H, Hayashi YK, Tsuburaya R, et al. Inflammatory changes in infantile-onset LMNA-associated myopathy. Neuromuscul Disord 2011; 21:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Sandre-Giovannoli A, Chaouch M, Kozlov S, et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet 2002; 70:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Sandre-Giovannoli A, Bernard R, Cau P, et al. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003; 300:2055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen L, Lee L, Kudlow BA, et al. LMNA mutations in atypical Werner's syndrome. Lancet 2003; 362:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navarro CL, De Sandre-Giovannoli A, Bernard R, et al. Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy. Hum Mol Genet 2004; 13:2493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muntoni F, Bonne G, Goldfarb LG, et al. Disease severity in dominant Emery Dreifuss is increased by mutations in both emerin and desmin proteins. Brain 2006; 129:1260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben Yaou R, Toutain A, Arimura T, et al. Multitissular involvement in a family with LMNA and EMD mutations: Role of digenic mechanism? Neurology 2007; 68:1883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emery AE. Emery-Dreifuss muscular dystrophy - a 40 year retrospective. Neuromuscul Disord 2000; 10:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonne G, Mercuri E, Muchir A, et al. Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. Ann Neurol 2000; 48:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carboni N, Mura M, Mercuri E, et al. Cardiac and muscle imaging findings in a family with X-linked Emery-Dreifuss muscular dystrophy. Neuromuscul Disord 2012; 22:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hopkins LC, Jackson JA, Elsas LJ. Emery-dreifuss humeroperoneal muscular dystrophy: an x-linked myopathy with unusual contractures and bradycardia. Ann Neurol 1981; 10:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rakovec P, Zidar J, Sinkovec M, et al. Cardiac involvement in Emery-Dreifuss muscular dystrophy: role of a diagnostic pacemaker. Pacing Clin Electrophysiol 1995; 18:1721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakata K, Shimizu M, Ino H, et al. High incidence of sudden cardiac death with conduction disturbances and atrial cardiomyopathy caused by a nonsense mutation in the STA gene. Circulation 2005; 111:3352.
          </a>
         </li>
         <li class="breakAll">
          Durmus H, Serdaroglu-Oflazer P, Deymeer F. Emery-Dreifuss muscular dystrophy: nuclear envelopathies. In: Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach, 2nd ed, Darras BT, Jones HR Jr, Ryan MM, De Vivo DC (Eds), Academic Press, San Diego 2015. p.667.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cattin ME, Muchir A, Bonne G. 'State-of-the-heart' of cardiac laminopathies. Curr Opin Cardiol 2013; 28:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vytopil M, Benedetti S, Ricci E, et al. Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomuscular phenotypes. J Med Genet 2003; 40:e132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finsterer J, Stöllberger C, Sehnal E, et al. Dilated, arrhythmogenic cardiomyopathy in emery-dreifuss muscular dystrophy due to the emerin splice-site mutation c.449 + 1G&gt;A. Cardiology 2015; 130:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bialer MG, Bruns DE, Kelly TE. Muscle enzymes and isoenzymes in Emery-Dreifuss muscular dystrophy. Clin Chem 1990; 36:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yates JR, Wehnert M. The Emery-Dreifuss Muscular Dystrophy Mutation Database. Neuromuscul Disord 1999; 9:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manilal S, Sewry CA, Man N, et al. Diagnosis of X-linked Emery-Dreifuss muscular dystrophy by protein analysis of leucocytes and skin with monoclonal antibodies. Neuromuscul Disord 1997; 7:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mora M, Cartegni L, Di Blasi C, et al. X-linked Emery-Dreifuss muscular dystrophy can be diagnosed from skin biopsy or blood sample. Ann Neurol 1997; 42:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merlini L. Selectivity of muscle sparing in Emery-Dreifuss muscular dystrophy. Neuromuscul Disord 2009; 19:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carboni N, Mura M, Marrosu G, et al. Muscle imaging analogies in a cohort of patients with different clinical phenotypes caused by LMNA gene mutations. Muscle Nerve 2010; 41:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubowitz V. Rigid spine syndrome: a muscle syndrome in search of a name. Proc R Soc Med 1973; 66:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finsterer J, Ramaciotti C, Wang CH, et al. Cardiac findings in congenital muscular dystrophies. Pediatrics 2010; 126:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Cid R, Ben Yaou R, Roudaut C, et al. A new titinopathy: Childhood-juvenile onset Emery-Dreifuss-like phenotype without cardiomyopathy. Neurology 2015; 85:2126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feingold B, Mahle WT, Auerbach S, et al. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. Circulation 2017; 136:e200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wicklund MP. The muscular dystrophies. Continuum (Minneap Minn) 2013; 19:1535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golzio PG, Chiribiri A, Gaita F. 'Unexpected' sudden death avoided by implantable cardioverter defibrillator in Emery Dreifuss patient. Europace 2007; 9:1158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dell'Amore A, Botta L, Martin Suarez S, et al. Heart transplantation in patients with Emery-Dreifuss muscular dystrophy: case reports. Transplant Proc 2007; 39:3538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aldwinckle RJ, Carr AS. The anesthetic management of a patient with Emery-Dreifuss muscular dystrophy for orthopedic surgery. Can J Anaesth 2002; 49:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takagi A, Nakase H. [Malignant hyperthermia-like reactions in Duchenne or Becker muscular dystrophy: review and hypothesis]. Rinsho Shinkeigaku 2008; 48:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wedel DJ. Malignant hyperthermia and neuromuscular disease. Neuromuscul Disord 1992; 2:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heiman-Patterson TD, Natter HM, Rosenberg HR, et al. Malignant hyperthermia susceptibility in X-linked muscle dystrophies. Pediatr Neurol 1986; 2:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voit T, Krogmann O, Lenard HG, et al. Emery-Dreifuss muscular dystrophy: disease spectrum and differential diagnosis. Neuropediatrics 1988; 19:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckley AE, Dean J, Mahy IR. Cardiac involvement in Emery Dreifuss muscular dystrophy: a case series. Heart 1999; 82:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickey RP, Ziter FA, Smith RA. Emery-Dreifuss muscular dystrophy. J Pediatr 1984; 104:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor MR, Fain PR, Sinagra G, et al. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol 2003; 41:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bialer MG, McDaniel NL, Kelly TE. Progression of cardiac disease in Emery-Dreifuss muscular dystrophy. Clin Cardiol 1991; 14:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waters DD, Nutter DO, Hopkins LC, Dorney ER. Cardiac features of an unusual X-linked humeroperoneal neuromuscular disease. N Engl J Med 1975; 293:1017.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6185 Version 16.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23622360" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Emery-Dreifuss muscular dystrophy, laminopathies, and other nuclear envelopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26786644" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A Systematic Review and Meta-analysis on the Epidemiology of the Muscular Dystrophies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21496632" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Emery-Dreifuss muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20182615" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Diseases of the nuclear envelope.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31840275" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Emery-Dreifuss muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8445613" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Emery-Dreifuss muscular dystrophy: linkage to markers in distal Xq28.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7894480" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8589715" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Emerin deficiency at the nuclear membrane in patients with Emery-Dreifuss muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10092874" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Distinct regions specify the nuclear membrane targeting of emerin, the responsible protein for Emery-Dreifuss muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19716112" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18179888" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21310615" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Four and a half LIM protein 1 gene mutations cause four distinct human myopathies: a comprehensive review of the clinical, histological and pathological features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22094483" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Reducing bodies and myofibrillar myopathy features in FHL1 muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10739764" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10080180" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22431096" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Autosomal recessive Emery-Dreifuss muscular dystrophy caused by a novel mutation (R225Q) in the lamin A/C gene identified by exome sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17761684" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Nesprin-1 and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21391237" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : TMEM43 mutations in Emery-Dreifuss muscular dystrophy-related myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21391237" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : TMEM43 mutations in Emery-Dreifuss muscular dystrophy-related myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23450819" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Genetic and clinical characteristics of skeletal and cardiac muscle in patients with lamin A/C gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10580070" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11138304" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14675861" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Apical left ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12673789" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Functional consequences of an LMNA mutation associated with a new cardiac and non-cardiac phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18551513" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : De novo LMNA mutations cause a new form of congenital muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18551513" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : De novo LMNA mutations cause a new form of congenital muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21632249" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Inflammatory changes in infantile-onset LMNA-associated myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11799477" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12702809" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Lamin a truncation in Hutchinson-Gilford progeria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12927431" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : LMNA mutations in atypical Werner's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15317753" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16585054" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Disease severity in dominant Emery Dreifuss is increased by mutations in both emerin and desmin proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17536044" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Multitissular involvement in a family with LMNA and EMD mutations: Role of digenic mechanism?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10838246" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Emery-Dreifuss muscular dystrophy - a 40 year retrospective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10939567" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21993399" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Cardiac and muscle imaging findings in a family with X-linked Emery-Dreifuss muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7294729" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Emery-dreifuss humeroperoneal muscular dystrophy: an x-linked myopathy with unusual contractures and bradycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7491318" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Cardiac involvement in Emery-Dreifuss muscular dystrophy: role of a diagnostic pacemaker.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15967842" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : High incidence of sudden cardiac death with conduction disturbances and atrial cardiomyopathy caused by a nonsense mutation in the STA gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15967842" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : High incidence of sudden cardiac death with conduction disturbances and atrial cardiomyopathy caused by a nonsense mutation in the STA gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23455585" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : 'State-of-the-heart' of cardiac laminopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14684700" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomuscular phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25502304" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Dilated, arrhythmogenic cardiomyopathy in emery-dreifuss muscular dystrophy due to the emerin splice-site mutation c.449 + 1G&gt;A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2311208" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Muscle enzymes and isoenzymes in Emery-Dreifuss muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10382916" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The Emery-Dreifuss Muscular Dystrophy Mutation Database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9132142" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Diagnosis of X-linked Emery-Dreifuss muscular dystrophy by protein analysis of leucocytes and skin with monoclonal antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9266737" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : X-linked Emery-Dreifuss muscular dystrophy can be diagnosed from skin biopsy or blood sample.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19423350" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Selectivity of muscle sparing in Emery-Dreifuss muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19882644" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Muscle imaging analogies in a cohort of patients with different clinical phenotypes caused by LMNA gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4697975" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Rigid spine syndrome: a muscle syndrome in search of a name.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20679303" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Cardiac findings in congenital muscular dystrophies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26581302" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A new titinopathy: Childhood-juvenile onset Emery-Dreifuss-like phenotype without cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28838934" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24305447" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The muscular dystrophies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17967828" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : 'Unexpected' sudden death avoided by implantable cardioverter defibrillator in Emery Dreifuss patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18089432" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Heart transplantation in patients with Emery-Dreifuss muscular dystrophy: case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11983660" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The anesthetic management of a patient with Emery-Dreifuss muscular dystrophy for orthopedic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18326302" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : [Malignant hyperthermia-like reactions in Duchenne or Becker muscular dystrophy: review and hypothesis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1483040" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Malignant hyperthermia and neuromuscular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3508709" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Malignant hyperthermia susceptibility in X-linked muscle dystrophies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3374765" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Emery-Dreifuss muscular dystrophy: disease spectrum and differential diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10377322" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Cardiac involvement in Emery Dreifuss muscular dystrophy: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6707817" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Emery-Dreifuss muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12628721" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Natural history of dilated cardiomyopathy due to lamin A/C gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2049891" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Progression of cardiac disease in Emery-Dreifuss muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1178008" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Cardiac features of an unusual X-linked humeroperoneal neuromuscular disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
